Raghav Sundar
@sundarraghav.bsky.social
📤 36
đź“Ą 18
đź“ť 15
GI Medical Oncologist. Stomach and esophageal cancer, and peritoneal metastases
Sharing our work in the spatial biology of HER2+ gastric cancer @GUTJournal_BMJ. Figuring out and targeting the tumor microenvironment is an exciting time for cancer therapeutics. @FilippoPietran4 @josephjzhao @KoheiShitara
gut.bmj.com/content/earl...
loading . . .
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy
Background Human epidermal growth factor receptor 2 (HER2; ERBB2 ) is overexpressed or amplified in 15–20% of gastric cancers (HER2+ GC). Within individual HER2+ GCs, HER2/ ERBB2 expression is often v...
https://gut.bmj.com/content/early/2025/10/30/gutjnl-2024-334667
about 1 month ago
0
1
0
Targeting Claudin18.2 beyond monoclonal antibodies like zolbetixumab is arriving! In this article by Samuel Klempner and myself in @NatureMedicine we discuss two promising Claudin18.2 targeting Antibody-Drug Conjugates.
www.nature.com/articles/s41...
loading . . .
Evolution of claudin18.2 therapies in gastroesophageal cancers - Nature Medicine
A pair of phase 1 trials evaluating antibody–drug conjugates identify potential strategies to treat advanced gastroesophageal cancers and highlight the rapid expansion of claudin18.2-targeting drug de...
https://www.nature.com/articles/s41591-025-03898-y
4 months ago
0
1
0
Grateful for this award from MASCC. We have been working closely with Paxman to build a device to reduce chemotherapy induced peripheral neuropathy. Awaiting results from ICE COMPRESS. This has been a massive team effort!
www.swog.org/clinical-tri...
@scalpcooling.bsky.social
5 months ago
0
3
1
Thrilled to share our latest Review on Gastric Cancer in the @TheLancet covering the latest in the treatment and management of this illness @LizzySmyth
@lizzysmyth.bsky.social
@HannekevanLaar1 @MarkarSheraz @YJanjigianMD & Izuma Nakayama.
www.thelancet.com/journals/lan...
loading . . .
Gastric cancer
Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than 650 000 deaths. Epidemiologically, gastric cancer shows substantial geogra...
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00052-2/fulltext
7 months ago
0
1
0
Excited to be in Chicago for
#AACR25
! Feels a little surreal to be at McCormick but not for ASCO! Looking forward to listening to some amazing science and breakthroughs in cancer biology and therapeutics. @KlempnerSam @josephjzhao
8 months ago
0
3
0
reposted by
Raghav Sundar
Yale Cancer Center
8 months ago
Thursday, April 24 at 6pm,
@sundarraghav.bsky.social
will moderate the next Yale GI Cancers
#CME
Webinar spotlighting
#GastroesophagealCancers
. Join for presentations + discussion from Drs. Daniel Boffa, Kevin Du, and Joanna Gibson. ➡️Register:
bit.ly/4jRXby5
@yaleschoolofmed.bsky.social
0
2
1
Honored to give the Keynote lecture at the Sixth Annual Paul R. O’Hara Esophagogastric Symposium in the University of Colorado Cancer Center. Sharing our work in gastroesophageal cancer and peritoneal metastases. Many thanks to Sunnie Kim for inviting me to speak!
8 months ago
0
1
0
Just published @JAMAJournal with Samuel Klempner and Jeeyun Lee.
jamanetwork.com/journals/jam...
Our Editorial on GEMSTONE-303 with sugemalimab and chemo. Key takeaway: PD-L1 inhibition shows similar efficacy to PD-1. More options for patients, but no clear advantage over existing treatments.
loading . . .
PD-1 or PD-L1 as First-Line Treatment of Metastatic Gastroesophageal Cancer
In the current issue of JAMA, Zhang and colleagues1 describe the role of sugemalimab—an anti–programmed death-ligand 1 (anti–PD-L1) monoclonal antibody—in combination with chemotherapy for first-line ...
https://jamanetwork.com/journals/jama/fullarticle/2830743
10 months ago
0
0
0
Shifting focus to B-cells in gastric cancer: Our study examines multiple cohorts and employs spatial profiling. This provides fresh insights into the tumor microenvironment, complementing T-cell focused studies of the TME
link.springer.com/article/10.1...
@RyanYKTay @josephjzhao
loading . . .
Spatial organization of B lymphocytes and prognosis prediction in patients with gastric cancer - Gastric Cancer
Background Within the tumor microenvironment (TME), the association of B lymphocytes (B cells) with prognosis and therapy response in gastric cancer (GC) remains poorly characterized. We investigated ...
https://link.springer.com/article/10.1007/s10120-025-01593-y?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=oa_20250219&utm_content=10.1007%2Fs10120-025-01593-y
10 months ago
0
2
0
Long overdue:our study showing concomitant scalp and limb cooling is safe and tolerable in patients using cryotherapy to prevent hair loss and neuropathy during chemotherapy. Important data supporting the phase 3 trial ongoing!
link.springer.com/article/10.1...
loading . . .
Safety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy - Supportive Care in Cancer
Introduction Scalp cooling is standard-of-care for prevention of chemotherapy-induced alopecia (CIA), with proven safety and efficacy. Limb cryotherapy has shown promise in preventing chemotherapy-ind...
https://link.springer.com/article/10.1007/s00520-024-08982-6?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=oa_20250212&utm_content=10.1007%2Fs00520-024-08982-6
10 months ago
0
1
0
Differential response to ICI based on sex in MSI-H & BRAF mut mCRC.
jitc.bmj.com/content/13/2...
loading . . .
Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
Background Immune checkpoint inhibitors (ICIs) are the gold standard therapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCR...
https://jitc.bmj.com/content/13/2/e010598.long
10 months ago
0
1
0
Inspired by Michael Cecchini, putting
@yalecancer.bsky.social
on the map at
#GI25
with some excellent abstracts and data. This study looking at ctDNA as a predictor of response to a novel ADC in mCRC!
11 months ago
0
0
0
So proud of @josephjzhao who won a merit award at ASCO GI 2025 for his work on profiling the tumor microenvironment of colorectal cancer peritoneal metastases!
11 months ago
0
0
0
Some ASCO GI 2025 posts coming up! Jackie Gaddy did an amazing job in piecing together the emerging role of ctDNA in colorectal cancer screening and surveillance!
11 months ago
0
1
1
Proud to publish in @CD_AACR:
aacrjournals.org/cancerdiscov...
. To understand the ecosystems and cancer maps in gastric cancer, we combined spatial transcriptomics and single cell sequencing to reveal distinct intratumoral spatial heterogeneity, immune environments, and genetic drivers
loading . . .
Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution
Abstract. Gastric cancer (GC) is a major cause of global cancer mortality with high levels of heterogeneity. To explore geospatial interactions in tumor ecosystems, we integrated 2,138 spatial transcr...
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-0605/750867/Spatially-Resolved-Tumor-Ecosystems-and-Cell
11 months ago
0
2
1
The next generation of biomarkers for immunotherapy will come from the tumor microenvironment (TME). Here we describe spatial TME predictors of response to IO in MSS colon cancer from the MAYA trial.
www.researchsquare.com/article/rs-5...
loading . . .
Spatial predictors of response to immunotherapy in microsatellite stable metastatic colorectal cancer
Microsatellite stable (MSS) colorectal cancers (CRC) are largely unresponsive to immune checkpoint inhibition (ICI), prompting investigation into strategies to enhance sensitivity. The MAYA trial, whi...
https://www.researchsquare.com/article/rs-5434411/v1
about 1 year ago
0
1
0
you reached the end!!
feeds!
log in
